Vitamin D receptor-Retinoid X receptor heterodimer (VDR-RXR)

The Vitamin D receptor-Retinoid X receptor (VDR-RXR) heterodimer is a fundamental nuclear receptor complex responsible for mediating the genomic effects of vitamin D [1]. It consists of the Vitamin D Receptor (VDR, NR1I1) and a Retinoid X Receptor (RXR, typically RXRA/NR2B1) partner [1]. Upon activation by its primary ligand, 1,25-dihydroxyvitamin D3, the heterodimer binds to specific DNA sequences called vitamin D response elements (VDREs) to regulate the expression of genes involved in calcium and phosphate transport, bone metabolism, and immune function [2][3]. This complex is a major therapeutic target for metabolic bone diseases, secondary hyperparathyroidism in chronic kidney disease, and hyperproliferative skin disorders like psoriasis [4]. Furthermore, its role in controlling cell cycle progression and apoptosis has made it a target of interest in cancer prevention and treatment [5]. Drugs targeting this complex include various vitamin D analogs (calcitriols) and rexinoids, though their use is often limited by the risk of inducing hypercalcemia [6].

Other names

VDR-RXR complexNR1I1-NR2B heterodimerVitamin D receptor-Retinoid X receptor complex

The VDR-RXR heterodimer functions as a ligand-activated transcription factor. Binding of 1,25-dihydroxyvitamin D3 to the VDR subunit induces a conformational change that promotes heterodimerization with RXR and the recruitment of co-activator proteins [1]. The complex then binds to Vitamin D Response Elements (VDREs) in the promoter regions of target genes to initiate or repress transcription, thereby regulating mineral metabolism and cellular growth [2][3].